TITLE

Bedaquiline: First FDA-approved tuberculosis drug in 40 years

AUTHOR(S)
Mahajan, Rajiv
PUB. DATE
January 2013
SOURCE
International Journal of Applied & Basic Medical Research;Jan2013, Vol. 3 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Johnson and Johnson's drug bedaquiline for the treatment of resistant tuberculosis. TB is reportedly more prevalent in India, China and Eastern Europe, and remains a global epidemic. The drug's anti-mycobacterial activity is said to be derived from inhibition of the proton pump of mycobacterial ATP synthase. Its potential risks are cited, including increased risk of death.
ACCESSION #
88046040

 

Related Articles

  • FDA Approves Johnson & Johnson Medication for HIV.  // Chain Drug Review;6/6/2011, Vol. 33 Issue 10, p45 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to Johnson & Johnson's (J&J) non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV infections treatment in New Brunswick, New Jersey.

  • Chain PHARMACY: REPORTERSNotebook.  // Drug Store News;6/27/2011, Vol. 33 Issue 8, p106 

    The article offers information on the approval of several drugs by the U.S. Food and Drug Administration that includes drug for urinary track infection by Amneal Pharmaceuticals LLC, drug for epilepsy by Mylan Inc., and antiretroviral treatment for HIV by Johnson & Johnson.

  • FDA Approves First New Tuberculosis Drug in 40 Years.  // India -- West;1/11/2013, Vol. 38 Issue 8, pA9 

    The article offers information on a tuberculosis drug by Johnson & Johnson which was approved by the U.S. Food and Drug Administration on December 31, 2012.

  • Faster pace lets FDA end year with 39 approvals. Weinstein, Deborah // Medical Marketing & Media;Feb2013, Vol. 48 Issue 2, p12 

    The article reports on the end-of-year approval made by the U.S. Food and Drug Administration (FDA) on December 28, 2012 of a green-lighting of Janssen's Sirturo drug for treatment-resistant tuberculosis (TB).

  • NEWS IN BRIEF. Passi, Gouri Rao // Indian Pediatrics;Feb2013, Vol. 50 Issue 2, p253 

    This section offers news briefs on medicine as of February 16, 2013. A decision was made by Glaxo Smith Kline to withdraw its advertisement about rotavirus diarrhea due to whistleblower Dr. Nalini Abraham. The U.S. Food and Drug Administration (FDA) approved the drug Bedaquiline for...

  • New treatment for drug-resistant TB okayed.  // Future Medicine;Feb2013, Vol. 2 Issue 2, p8 

    The article reports on the approval of the U.S. Food and Administration (FDA) on the use of the drug Sirturo for the treatment of multi-drug resistant (MDR) tuberculosis.

  • FDA recommends accelerated approval of bedaquiline for MDR-TB.  // Infectious Disease News;Dec2012, Vol. 25 Issue 12, p1 

    The article reports on the decision of the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to recommend the approval of bedaquiline for the treatment of multidrug-resistant Mycobacterium tuberculosis.

  • First novel anti-tuberculosis drug in 40 years. Osborne, Randy // Nature Biotechnology;Feb2013, Vol. 31 Issue 2, p89 

    The article offers information on the approval of a new drug by the U.S. Food and Drug Administration (FDA) to treat tuberculosis and also mentions that it is the first anti-mycobacterial compound with a novel mechanism.

  • Sirturo OK'd for Tuberculosis.  // Monthly Prescribing Reference;Jan2013, Vol. 29 Issue 1, pA14 

    The article offers information on the approval of a drug Sirturo from Janssen LP by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics